Remote Ischemic Conditioning Device Tested for Chronic Kidney Disease
Tests a remote ischemic conditioning device in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with chronic kidney disease who have not needed dialysis. It tests whether remote ischemic conditioning, short repeated pauses of blood flow in the arm, protects kidney function.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease with eGFR of 15 ml/min/1.73m2 or more and 24-hour urine protein of 3.5 g or less.
- Earlier treatment
- People who have had kidney replacement treatment in the past cannot join.
Main reasons for not taking part
- Nephrotic syndrome or acute kidney injury
- Past kidney replacement treatment
- Diabetes or glycated hemoglobin above 8% (64 mmol/mol)
- Severe heart problems or uncontrolled high blood pressure
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Where in China
- Chinese PLA General HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Yuanjun Yang
- Trial code
- NCT06501222
- Record updated
- 19 August 2024
- Original description
The incidence of Chronic kidney disease (CKD) is showing an upward trend, but the therapeutic effect of treatment is limited. Remote ischemic conditioning (RIC) has the potential to safeguard remote organs via the repeated application of brief ischemic stimuli. the aim of our study is to investigate whether RIC can protect the renal function in patients with CKD.Read full original descriptionShow less
The Renal Protective Effects of Remote Ischemic Preconditioning in Patients With Chronic Kidney Disease: Randomized, Parallel-controlled, proof-of Concept Trial
The incidence of Chronic kidney disease (CKD) is showing an upward trend, but the therapeutic effect of treatment is limited. Remote ischemic conditioning (RIC) has the potential to safeguard remote organs via the repeated application of brief ischemic stimuli. the aim of our study is to investigate whether RIC can protect the renal function in patients with CKD.
Inclusion: CKD Patients with eGFR ≥ 15ml/min/1.73m2; Age ≥ 18 years old; 24-hour urine protein excretion ≤ 3.5g; Subjects who have signed the informed consent form.
Exclusion: Patients who may have medication changes during RIC or sham-RIC intervention; Patients with cardiogenic embolism (atrial fibrillation) or other severe arrhythmias (severe bradycardia, third-degree atrioventricular block, or ventricular tachycardia), previous myocardial infarction, or severe heart failure (New York Heart Association Class III and IV); Patients with nephrotic syndrome; Patients with contraindications to RIC, such as vascular injury, soft tissue injury, fracture, infection, or known peripheral vascular disease in both arms; Patients with a history of hemostatic disorders, systemic bleeding, or thrombocytopenia; Uncontrolled hypertension (defined as systolic blood pressure ≥ 200 mmHg despite antihypertensive treatment); Patients with respiratory failure, malignant tumors, or other autoimmune diseases; Patients with a history of diabetes or glycated hemoglobin > 8%; Patients with familial hypercholesterolemia (>5.5 mmol/L) accompanied by high low-density lipoprotein (>2.5 mmol/L); Patients with acute kidney injury; Patients who have undergone renal replacement treatment in the past; Women who are pregnant or breastfeeding at the time of enrollment or any time during the study.